Drug Profile
Savolitinib - AstraZeneca/HUTCHMED
Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; VoressaLatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
- Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Renal cell carcinoma
- Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
- No development reported CNS cancer; Solid tumours
Most Recent Events
- 01 Mar 2024 AstraZeneca suspendes the phase II SOUND trial in Non-small cell lung cancer (Combination therapy, In adults, In children, In adolescents, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) due to sponsor's decision to evaluate risks and benefits of the study (NCT05374603)
- 28 Feb 2024 Registered for Non-small cell lung cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Macau (PO)
- 28 Feb 2024 HUTCHMED in collaboration with AstraZeneca announces intention to submit new drug application (NDA) to US FDA for Non small cell lung cancer in tne first quarter of 2024